SK Chemicals & Pharma to commercialize Fentanyl Taifun for Korea and China

Published: 2004-11-29 06:58:00

Updated: 2004-11-29 06:58:00

SK Chemicals & Pharma said on November 24 that they have entered into a licensing and development agreement with LAB International Inc. in Turku, Finland, for Fentanyl Taifun, LAB's fast-acting Fentanyl formulation delivered using the company's approved Taifun dry powder inhaler platform.

Fent...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK